ATF4 and osteosarcoma: The absence of RET upregulates ATF4, which accelerates the turnover of RET proteasomes by over-recruitment of its trans-activated E3 ligase CPL-C, thereby enhancing the chemotherapy effect of BTZ and preventing BTZ resistance in osteosarcoma cells.